Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Why Praluent is the Optimal Choice for Post-ACS Patients?

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Why Praluent is the Optimal Choice for Post-ACS Patients?

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Why Praluent is the Optimal Choice for Post-ACS Patients?

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Why Praluent is the Optimal Choice for Post-ACS Patients?

Why Praluent is the Optimal Choice for Post-ACS Patients?

Explore the compelling reasons why Praluent should be your first choice for patients with recent acute coronary syndrome who need to achieve their LDL-C goals. This informative video provides in-depth clinical insights and evidence, detailing how Praluent’s unique mechanism of action and proven efficacy can significantly improve patient outcomes. The video also covers tips on the 3 main factors: efficacy, safety, and administration to help you to integrate Praluent into your treatment plans. Enhance patient outcomes and elevate your practice with Praluent.

Diabetes in Asians: Tailoring Management to Unique Metabolic Profiles

Diabetes in Asians: Tailoring Management to Unique Metabolic Profiles

Protecting the Future: Italy’s National Screening Law for Type 1 Diabetes 

Protecting the Future: Italy’s National Screening Law for Type 1 Diabetes 

Professor Emanuele Bosi discusses a mandatory screening program for Type 1 diabetes and celiac disease in children and adolescents, launched in Italy in 2024.

Diabetes in Asians: Tailoring Management to Unique Metabolic Profiles

Diabetes in Asians: Tailoring Management to Unique Metabolic Profiles

¿HiperCKemia?

¿HiperCKemia?

La hiperCKemia (CK) suele indicar la presencia de un trastorno neuromuscular subyacente,
que puede manifestarse en pacientes desde la infancia hasta la edad adulta, como en el caso
de la enfermedad de Pompe que puede presentarse en pacientes de todas las edades.

Abordar los síntomas de la RA ayuda a mejorar la vida cotidiana de los niños

Abordar los síntomas de la RA ayuda a mejorar la vida cotidiana de los niños

Allegra - mucho más que solo alivio de síntomas

Allegra - mucho más que solo alivio de síntomas

No todos los antihistamínicos  'no sedantes' son iguales

No todos los antihistamínicos 'no sedantes' son iguales

Emanuele Bosi

Emanuele Bosi

Professor of Internal Medicine, Head of Diabetes, San Raffaele Vita Salute University Hospital, Milan, Italy​